CareDx Appoints New CMO, Adds Director
Ticker: CDNA · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1217234
Sentiment: neutral
Topics: leadership-change, board-appointment, executive-appointment
TL;DR
CareDx shakes up leadership with a new CMO and board member.
AI Summary
CareDx, Inc. announced on April 15, 2024, the appointment of Dr. Veronica Miller as Chief Medical Officer and the election of Dr. Michael J. Hostetter to its Board of Directors. The company also reported that Dr. John L. Reynolds will transition from Chief Medical Officer to a strategic advisor role. These changes are effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member suggests a strategic shift or reinforcement of leadership within CareDx, potentially impacting its future research and development or market strategy.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- CareDx, Inc. (company) — Registrant
- Dr. Veronica Miller (person) — Appointed Chief Medical Officer
- Dr. Michael J. Hostetter (person) — Elected to Board of Directors
- Dr. John L. Reynolds (person) — Transitioning from Chief Medical Officer to Strategic Advisor
- April 15, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer for CareDx?
Dr. Veronica Miller has been appointed as the new Chief Medical Officer for CareDx.
Who has been elected to the Board of Directors at CareDx?
Dr. Michael J. Hostetter has been elected to the Board of Directors at CareDx.
What is Dr. John L. Reynolds' new role?
Dr. John L. Reynolds will transition from Chief Medical Officer to a strategic advisor role.
When are these leadership changes effective?
The leadership changes are effective as of April 15, 2024.
What was CareDx's former company name?
CareDx, Inc.'s former company names were XDx, Inc. and EXPRESSION DIAGNOSTICS INC.
Filing Stats: 1,721 words · 7 min read · ~6 pages · Grade level 9.9 · Accepted 2024-04-16 16:20:02
Key Financial Figures
- $0.001 — nge on which registered) Common Stock, $0.001 Par Value CDNA The Nasdaq Stock Mar
- $675,000 — nna's initial annualized salary will be $675,000, and he will be eligible to receive an
- $4,000,000 — on"), having a grant date fair value of $4,000,000, which option will vest over four years
Filing Documents
- d822701d8k.htm (8-K) — 37KB
- d822701dex101.htm (EX-10.1) — 15KB
- d822701dex102.htm (EX-10.2) — 103KB
- d822701dex103.htm (EX-10.3) — 77KB
- d822701dex991.htm (EX-99.1) — 7KB
- g822701g0415210914166.jpg (GRAPHIC) — 3KB
- 0001193125-24-097776.txt ( ) — 430KB
- cdna-20240415.xsd (EX-101.SCH) — 3KB
- cdna-20240415_lab.xml (EX-101.LAB) — 18KB
- cdna-20240415_pre.xml (EX-101.PRE) — 11KB
- d822701d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter, dated March 24, 2024, between CareDx, Inc. and John Hanna. 10.2 Change of Control and Severance Agreement, dated March 25, 2024, between CareDx, Inc. and John Hanna. 10.3 Confidential Information, Invention Assignment, Non-Competition, and Arbitration Agreement, dated March 24, 2024, between CareDx, Inc. and John Hanna. 99.1 Press release dated April 16, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). -3-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 16, 2024 CAREDX, INC. By: /s/ Abhishek Jain Abhishek Jain Chief Financial Officer -4-